---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-23-000123"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T15:32:37.904500+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Caribou Biosciences Q3 net loss $10M, cash $396.7M; pipeline advances with CB-010, CB-011, CB-012

## Summary
- Net loss of $10.0M for Q3 2023 vs $26.6M in Q3 2022; revenue $23.7M (incl. $21.5M from AbbVie termination).
- Cash, equivalents, and marketable securities $396.7M as of Sept 30, 2023; funding expected into Q4 2025.
- CB-010 ANTLER trial dose expansion continues; FDA meeting for pivotal trial planned, data H1 2024.
- CB-011 CaMMouflage trial at dose level 2; CB-012 IND cleared, enrollment expected by mid-2024.
- Completed $134.4M follow-on offering and received $25M Pfizer investment in Q3 2023.

## SEC filing metadata
- accession: 0001619856-23-000123
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000123/0001619856-23-000123-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000123/crbu-20231107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-23-000123
- JSON: https://secwatch.observer/filing/0001619856-23-000123.json
- Plain text: https://secwatch.observer/filing/0001619856-23-000123.txt

## Key facts
- Earnings Releases
  Caribou Biosciences, Inc. reported third quarter of 2023 results: revenue $23.7 million.
  - Period: third quarter of 2023
  - Revenue: $23.7 million
  - Result: reported results
  source text: will be sufficient to fund its current operating plan into Q4 2025. Licensing and collaboration revenue: Revenue from Caribou’s licensing and collaboration agreements was $23.7 million for the three months ended September 30, 2023, compared to $3.3 2 million for the same period 2022. The increase was primarily due to $21.5 million in revenue recognized under
  evidence_url: https://www.sec.gov/Archives/edgar/data/1619856/000161985623000123/0001619856-23-000123-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.